MB
ARQT icon

MPM BioImpact’s Arcutis Biotherapeutics ARQT Stock Holding History

MPM BioImpact’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-733,966
Closed -$17.3M – 40
2026
Q1 		$17.3M Buy
733,966
+202,766
+38% +$5.17M 1.34% 31
2025
Q4 		$15.4M Buy
+531,200
New +$13.6M 1.77% 27
2023
Q2 		– Sell
-254,137
Closed -$2.8M – 35
2023
Q1 		$2.8M Sell
254,137
-7,932
-3% -$115K 0.73% 25
2022
Q4 		$3.88M Buy
262,069
+4,884
+2% +$85.3K 1.01% 22
2022
Q3 		$4.92M Sell
257,185
-1,315
-0.5% -$29.8K 1.16% 21
2022
Q2 		$5.51M Hold
258,500
– – 1.53% 19
2022
Q1 		$4.98M Buy
+258,500
New +$4.37M 1.34% 20

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

MPM BioImpact's ARQT Position: Q2 2026 in Review

MPM BioImpact sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 733,966 shares — an estimated $17.3M sold.

MPM BioImpact first reported a position in ARQT in Q1 2022 and held it in 7 quarters. The position peaked at $17.3M in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • MPM BioImpact reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • MPM BioImpact sold 733,966 Arcutis Biotherapeutics shares in Q2 2026, an estimated $17.3M.
  • MPM BioImpact first reported a position in Arcutis Biotherapeutics in Q1 2022 and held it in 7 quarters.
  • MPM BioImpact's Arcutis Biotherapeutics position peaked at $17.3M in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.